This information is intended for use by health professionals
E45 Itch Relief Cream
Cetyl Alcohol (present in Cetyl Palmitate)
For the full list of excipients, see section 6.1
For the treatment of pruritus, eczema, dermatitis, and scaling skin conditions where an antipruritic and/or hydrating effect is required. It may also be used for the continued treatment and follow-up treatment of these skin diseases.
E45 Itch Relief Cream should be applied to each affected area twice a day. The duration of treatment depends on the clinical response.
There is no indication that the dosage needs to be modified for the elderly.
Children and infants over the age of 1 month:
There is no indication that the dosage needs to be modified for children or babies.
Method of administration
Topical application to the skin.
Patients with known hypersensitivity lauromacrogols, urea or to any of the excipients listed in section 6.1. It should not be used to treat acute erythroderma, acute inflammatory, oozing or infected skin lesions.
For external use only.
Avoid contact with the mucous membranes and eyes. Irritation (e.g. erythema, burning) may occur if applied to broken or inflamed skin. Discontinue use if irritation or rash occurs.
E45 Itch Relief Cream may cause irritation if applied to broken or inflamed skin.
Contains: Cetyl Alcohol (present in Cetyl Palmitate), which may cause local skin reactions (e.g. contact dermatitis). Contains: 1% Benzyl Alcohol, which may cause mild local irritation.
Instruct patients not to smoke or go near naked flames – risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.
Urea may increase penetration through the skin barrier of other topically applied medicines (e.g. corticosteroids, dithranol and fluorouracil) when used at the same time.
There are no or limited amount of data from the use of lauromacrogols and urea in pregnant women. Urea has been reported to cross the placenta. However, exposure to the foetus is expected to be negligible from topical application. There are no specific restrictions concerning its use during pregnancy.
There are no or limited amount of data from the use of lauromacrogols and urea in breast-feeding women. But, systemic exposure is expected to be negligible from topical application. It is not to be used on the breasts immediately prior to breast feeding during lactation.
No data on human fertility is available for urea or lauromacrogols.
Adverse events which have been associated with urea; lauromacrogols are given below, tabulated by system organ class and frequency. Frequencies are defined as: Very common (≥1/10); Common (≥1/100 and <1/10); Uncommon (≥1/1000 and <1/100); Rare (≥1/10,000 and <1/1000); Very rare (< 1/10,000); Not known (cannot be estimated from the available data). Within each frequency grouping, adverse events are presented in order of decreasing seriousness.
System Organ Class
Immune System Disorders
Skin and Subcutaneous Tissue Disorders
Application site pustules; skin burning sensation; pruritus; erythema; dermatitis allergic
Reporting of Suspected Adverse Reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Overdose is very unlikely with a topical cream.
If overdose is suspected in young children or babies, seek the advice of a healthcare professional, since blood-urea concentrations may increase.
In the unlikely event of an overdose, treatment should be symptomatic and supportive.
Pharmacotherapeutic group: Antipruritics, Incl. Antihistamines, Anaesthetics, etc.; Other Antipruritics;
ATC Code: D04AX
Urea is a physiological product derived from human protein metabolism. It is found naturally in the skin and when applied topically it can increase the horny layer's capacity to retain water. E45 Itch Relief Cream has been shown to increase skin hydration and when used as recommended provides hydration for 24 hours. Patients with eczema and psoriasis have been shown to have decreased levels of urea in their skin. Urea is not allergenic and is well-tolerated at a concentration of 5%.
Lauromacrogols have the properties of a topical anaesthetic and have an antipruritic effect. The local tolerability of lauromacrogols is good.
E45 Itch Relief Cream has also been shown to increase the lipid content of the epidermis thus, soothing and smoothing the skin.
Little urea is absorbed after topical application. It is mainly excreted in the urine, and to a lesser extent in perspiration.
There is no evidence of systemic availability of lauromacrogols after topical administration.
No specific studies have been performed with E45 Itch Relief Cream. Urea and lauromacrogols have been used therapeutically for many years in humans. Information from animal studies are unlikely to provide any further relevant information.
Dimeticone, phenyl dimeticone, liquid paraffin, cetyl palmitate (includes cetyl alcohol), stearic palmitic acid, octyldodecanol, glycerol 85%, polysorbate, carbomer, trometamol, benzyl alcohol, purified water.
Do not store above 25°C.
Aluminium tubes with double internal lacquer of epoxy phenol resin and closure made of polyoxyethylene. Content: 10g, 35g, 50g, 60g, 75g, 100g and 110g.
Plastic pump dispensers. Content: 175g, 200g and 500g.
A pump pack, made of polypropylene and polyethylene, consisting of a piston
pump system with an airless dispenser. Pack size: 500g
Not all pack sizes are necessarily marketed.
Crookes Healthcare Limited
Trading as Crookes Healthcare
1 Thane Road West
19 October 1999